Capped analogs for self-replicating mRNA and uses thereof
By providing a capped analog suitable for self-replicating mRNA, the problem of low in vivo stability and translation efficiency of self-replicating mRNA in the prior art is solved, and the effect of significantly improving its in vitro transcription yield and translation efficiency is achieved.
CN120082547AActive Publication Date: 2025-06-03BEIJING YUEKANGKECHUANG PHARM TECH CO LTD
6 Cites 1 Cited by
Patent Information
- Application Number
- CN202510570674.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-06
- Publication Date
- 2025-06-03
- Estimated Expiration
- 2045-05-06
AI Technical Summary
Technical Problem
The prior art is difficult to provide capped analogs suitable for self-replicating mRNAs, resulting in low stability and translation efficiency in vivo.
Method used
A compound, specifically structured as a compound represented by formula (I), and its stereoisomers or pharmaceutically acceptable salts, is provided for as capping analogs of self-replicating mRNA, improving its stability and translation efficiency in vivo.
Benefits of technology
By using this capped analog, the in vitro transcription yield and integrity of self-replicating mRNA were significantly improved and its translation efficiency was significantly improved.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention provides a capped analogue for self-replicating mRNA and application of the capped analogue. The capped analogue for the self-replicating mRNA can improve the stability of the self-replicating mRNA and / or the translation efficiency of the self-replicating mRNA.
Need to check novelty before this filing date? Find Prior Art